New York State Common Retirement Fund Has $20.45 Million Position in Humana Inc. (NYSE:HUM)

New York State Common Retirement Fund grew its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 4.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 77,282 shares of the insurance provider's stock after buying an additional 3,100 shares during the period. New York State Common Retirement Fund owned about 0.06% of Humana worth $20,449,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Riverview Trust Co bought a new position in Humana during the first quarter worth $34,000. Garde Capital Inc. acquired a new stake in shares of Humana during the first quarter worth $36,000. Transce3nd LLC acquired a new stake in shares of Humana during the fourth quarter worth $38,000. Whipplewood Advisors LLC lifted its position in shares of Humana by 639.1% in the 1st quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock worth $45,000 after buying an additional 147 shares during the last quarter. Finally, Colonial Trust Advisors boosted its holdings in shares of Humana by 4,500.0% in the 4th quarter. Colonial Trust Advisors now owns 184 shares of the insurance provider's stock valued at $47,000 after buying an additional 180 shares during the period. Institutional investors and hedge funds own 92.38% of the company's stock.

Wall Street Analysts Forecast Growth

HUM has been the topic of a number of recent research reports. Mizuho raised their target price on shares of Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a report on Wednesday, April 9th. Raymond James Financial raised Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price target on the stock in a report on Thursday, May 1st. Robert W. Baird upped their price objective on Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 15th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $290.00 target price on shares of Humana in a research report on Thursday, May 1st. Finally, Wall Street Zen downgraded shares of Humana from a "buy" rating to a "hold" rating in a report on Saturday, July 12th. Seventeen research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Humana has a consensus rating of "Hold" and an average target price of $282.57.

Humana Trading Down 1.6%

Shares of NYSE HUM traded down $3.47 during mid-day trading on Friday, hitting $220.08. 4,319,955 shares of the company traded hands, compared to its average volume of 1,821,967. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.71. Humana Inc. has a 1 year low of $207.93 and a 1 year high of $406.09. The stock has a market capitalization of $26.56 billion, a price-to-earnings ratio of 15.56, a PEG ratio of 1.53 and a beta of 0.44. The business has a 50 day moving average of $234.87 and a two-hundred day moving average of $257.23.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, beating analysts' consensus estimates of $10.07 by $1.51. The company had revenue of $32.11 billion during the quarter, compared to analyst estimates of $32 billion. Humana had a net margin of 1.42% and a return on equity of 14.47%. The business's quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the firm earned $7.23 earnings per share. On average, sell-side analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.